MGI/SuperGen’s Dacogen Is “Approvable” Pending Transfusion Data Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies expect to submit requested data to FDA early in the fourth quarter for the myelodysplastic syndromes therapy.
You may also be interested in...
MGI/SuperGen’s Dacogen On Deck For Late May Launch
The myelodysplastic syndromes therapy could post $25 mil. in 2006 sales, MGI said following the May 3 approval.
MGI/SuperGen’s Dacogen On Deck For Late May Launch
The myelodysplastic syndromes therapy could post $25 mil. in 2006 sales, MGI said following the May 3 approval.
MGI’s Oral Mucositis Therapy Saforis NDA Submitted
The firm had planned to file the application for glutamine in the third quarter of 2005.